As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

GLP-1 medications like Ozempic and Wegovy are ... Picture this: You start a medication for diabetes management, and suddenly you’re crossing marathon finish lines. This isn’t just a fairy ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 11, 2024 DALLAS, Nov. 11, 2024 — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...